Edition:
United States

Emergent BioSolutions Inc (EBS.N)

EBS.N on New York Stock Exchange

54.30USD
11:36am EDT
Change (% chg)

$-0.43 (-0.79%)
Prev Close
$54.73
Open
$54.77
Day's High
$54.95
Day's Low
$53.79
Volume
9,946
Avg. Vol
126,301
52-wk High
$55.94
52-wk Low
$33.26

Select another date:

Thu, May 3 2018

BRIEF-Emergent BioSolutions Reports Q1 Adjusted Loss Per Share $0.03

* EMERGENT BIOSOLUTIONS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS

BRIEF-Emergent BioSolutions ‍Appoints Richard Lindahl As New Executive Vice President And Chief Financial Officer​

* EMERGENT BIOSOLUTIONS ANNOUNCES EXECUTIVE MANAGEMENT CHANGES THAT ENHANCE EXECUTION OF COMPANY’S GROWTH STRATEGY

BRIEF-Emergent Biosolutions To Implement Stock Repurchase Program

* EMERGENT BIOSOLUTIONS TO IMPLEMENT STOCK REPURCHASE PROGRAM FOR UP TO $50 MILLION OF ITS COMMON STOCK

BRIEF-Emergent Biosolutions Awarded One-Year CDC Contract Valued At $26 Mln

* EMERGENT BIOSOLUTIONS AWARDED ONE-YEAR CDC CONTRACT VALUED AT $26 MILLION FOR VACCINIA IMMUNE GLOBULIN PROGRAM

BRIEF-Emergent Biosolutions And Valneva Initiate Clinical Study To Evaluate Vaccine Against Zika Virus

* EMERGENT BIOSOLUTIONS AND VALNEVA INITIATE PHASE 1 CLINICAL STUDY TO EVALUATE VACCINE CANDIDATE AGAINST ZIKA VIRUS

BRIEF-Valneva And Emergent Biosolutions Start Phase 1 Clinical Study To Evaluate Vaccine Candidate Against Zika Virus

* EMERGENT BIOSOLUTIONS AND VALNEVA INITIATE PHASE 1 CLINICAL STUDY TO EVALUATE VACCINE CANDIDATE AGAINST ZIKA VIRUS

BRIEF-Emergent BioSolutions Q4 Earnings Per Share $0.67

* EMERGENT BIOSOLUTIONS REPORTS FOURTH QUARTER AND TWELVE MONTHS 2017 FINANCIAL RESULTS

Select another date: